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Abstract Only a fraction of cancer patients benefits from immune checkpoint inhibitors. This
may be partly due to the dense extracellular matrix (ECM) that forms a barrier for T cells.
Comparing five preclinical mouse tumor models with heterogeneous tumor microenvironments, we
aimed to relate the rate of tumor stiffening with the remodeling of ECM architecture and to
determine how these features affect intratumoral T cell migration. An ECM-targeted strategy,
based on the inhibition of lysyl oxidase, was used. In vivo stiffness measurements were found to be
strongly correlated with tumor growth and ECM crosslinking but negatively correlated with T cell
migration. Interfering with collagen stabilization reduces ECM content and tumor stiffness leading
to improved T cell migration and increased efficacy of anti-PD-1 blockade. This study highlights the
rationale of mechanical characterizations in solid tumors to understand resistance to
immunotherapy and of combining treatment strategies targeting the ECM with anti-PD-1 therapy.
Introduction
In the last decade, significant progress has been made in the development of T-cell-based immuno-
therapies (Miller and Sadelain, 2015). The two main T-cell-based immunotherapies are adoptive T
cell therapy and immune checkpoint inhibitors. Monoclonal antibodies blocking the immune check-
points cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death one receptor
(PD-1) have quickly gone from proof of concepts to FDA-approved first- and second-line treatments
for a significant number of tumors even in late stages (Callahan et al., 2016). However, an elevated
percentage of patients with solid tumors fail to respond to these therapies. The mechanisms
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underlying the poor response to immune checkpoint inhibitors are still uncertain; nevertheless,
recent results suggest that T cell function and distribution in the tumor are affected by numerous
immunosuppressive mechanisms (Anderson et al., 2017). It is well established that in progressing
tumors T cells exhibit a particular phenotype unable to normally respond to tumor antigens. In addi-
tion, in a large proportion of tumors, T lymphocytes are excluded from the tumor cell regions in a
so-called ‘excluded-immune profile’ (Hegde et al., 2016; Herbst et al., 2014; Joyce and Fearon,
2015). Ineffective T cell migration and penetration into the tumor mass might represent an impor-
tant obstacle to T cell-based immunotherapies. As a support for this notion, various clinical studies
have shown that tumors enriched in T cells are more susceptible to be controlled by PD-1 blockade.
In contrast, tumors with so-called immune-excluded profiles, in which T cells are present within
tumors but not in contact with malignant cells, are refractory to PD-1 blockade (Herbst et al., 2014;
Mariathasan et al., 2018). Particularly, the fibrotic state of desmoplastic tumors can cause immuno-
suppression through multiple mechanisms (Turley et al., 2015). The hypothesis of physical resistance
to T cell infiltration and migration-related to the heterogeneity and aberrant organization of the
extracellular matrix (ECM) with respect to the tumor nests has emerged recently (Jiang et al., 2017;
Pickup et al., 2014). By using dynamic imaging microscopy, we highlighted the detrimental impact
of collagen fibrils architecture on the migratory behavior of T cells in fresh human tumor explants.
Both a guiding strategy combined with a physical hindrance process has been shown to restrain T
cells from contacting tumor cells, thus leading to the T cell excluded profile (Salmon et al., 2012;
Peranzoni et al., 2013). Hence, a dense fibrotic stroma could raise physical obstacles to immune
cell infiltration similar to the previously established stromal resistance to chemotherapeutics, anti-
bodies, nanoparticles, or virus tumor penetration (Netti et al., 2000; Stylianopoulos et al., 2018).
In addition, cellular components of tumor-associated fibrosis, particularly the cancer-associated
fibroblasts (CAF), can have both direct and indirect effects on T cell infiltration and function
(Turley et al., 2015). Accordingly, one important challenge in the field is to develop strategies tar-
geting tumor fibrosis in order to reverse immune exclusion and to improve T cell-based immunother-
apy. Recent studies have been undertaken with this objective. T cells engineered to express a
chimeric antigen receptor together with heparanase, an ECM-degrading enzyme, show enhanced
infiltration into xenografted tumors as well as anti-tumor efficacy (Caruana et al., 2015). Recently, a
major role for the TGFb signaling pathway in promoting T cell exclusion from tumor cells has been
demonstrated. In breast and colorectal mouse tumor models, neutralizing antibodies against TGFb
were shown to reduce collagen I production, overcoming the T cell excluded profile and increasing
the efficacy of anti-PD-L1 antibodies (Mariathasan et al., 2018; Tauriello et al., 2018). In cholangio-
carcinoma, an immune mesenchymal subtype has been identified, which is associated with TGFb sig-
nature and poor tumor-infiltrating cells (Job et al., 2020). Other axes including the CXCR4/CXCL12
in breast metastasis and the focal adhesion kinase in pancreatic ductal adenocarcinoma (PDAC) have
also been associated with both desmoplasia and absence of cytotoxic T lymphocytes in tumors from
mice (Chen et al., 2019). Consequently, the inhibition of these axes in preclinical mouse cancer
models was shown to reduce fibrosis while significantly increasing T cell infiltration and improving
response to checkpoint inhibitors (Mariathasan et al., 2018; Tauriello et al., 2018; Incio et al.,
2015; Jiang et al., 2016). Clinical trials testing such combination are currently ongoing in advanced
pancreatic cancer, mesothelioma, urothelial carcinoma, and other malignancies (NCT02546531,
NCT02758587, NCT02734160, NCT04064190, and NCT02947165).
However, due to patient and tumor heterogeneity, there is no clear indication of how the T cell
distribution in tumors is related to the fibrosis level and to the different architectures of ECM. Thus,
there is an urgent need to assist in matching combination approaches to patient populations who
could benefit from stromal modulation strategies to improve their response to immunotherapy.
Companion matrix-derived biomarkers and imaging approaches should provide insights into the
contribution of ECM remodeling in shaping the immune milieu of the tumor. Particularly, a critical
determinant of fibrotic tumor progression – the tumor mechanics – has been poorly investigated
through the prism of immune impact. An important feature of fibrotic tumors is their considerable
higher stiffness compared to their neighboring healthy tissues, which are highly correlated with can-
cer progression and metastasis, particularly in breast, colorectal, liver, and pancreatic tumors
(Venkatesh et al., 2008; Samani et al., 2007). The use of non-invasive imaging techniques such as
shear wave elastography (SWE) and magnetic resonance elastography, designed to monitor stiffness
of any given tissue, allows an accurate and non-invasive diagnostic and characterization of malignant
Nicolas-Boluda et al. eLife 2021;10:e58688. DOI: https://doi.org/10.7554/eLife.58688 2 of 29
Research article Cancer Biology
lesions in vivo with prognostic significance, for instance in breast cancer (Evans et al., 2012;
Song et al., 2018; Riegler et al., 2018). Indeed, the extensive remodeling of the stromal compo-
nents which increase tumor stiffness can mechanically activate intracellular signaling pathways that
promote tumor progression and at the same time can dampen T cell functions including migration
and infiltration into tumor islets (Datar and Schalper, 2016; Humphrey et al., 2014; Krebs et al.,
2017; Rice et al., 2017). However, there is a lack of studies correlating the mechanical properties of
tumors to their heterogeneous ECM architecture and T cell infiltration capacity. Here we aim at fill-
ing this gap through a comprehensive investigation of stiffness evolution in several preclinical mouse
models of pancreatic, breast, and bile duct carcinomas, presenting different ECM organizations,
coupled with dynamic imaging of fresh tumor slices to monitor T cell motility. In concert with these
imaging biomarkers of both mechanical properties, ECM architecture, and T cell migration, we
explored the consequences of altering the ECM by inhibition of the lysyl oxidase (LOX), a copper-
dependent enzyme responsible for the crosslinking of collagen molecules into fibers that has been
seen to be overexpressed in many metastatic tumors and responsible for malignant progression
(Cox et al., 2016). We highlight that LOX inhibition has different mechanical modulating effects
depending on the ECM architecture, with significant improvement in T cell mobility. Despite minor
effects in primary tumor growth upon LOX inhibition or PD-1 blockade treatment alone, their combi-
nation increases effector CD8 T cell accumulation in tumors and significantly delays tumor progres-
sion in a pancreatic cancer model.
Results
Relationship between tumor structure and tumor mechanical properties
in different preclinical carcinoma mouse models
One key aspect when testing immunotherapeutic agents is the use of relevant preclinical models
that closely mimic the properties of human solid tumors. Human carcinomas derive from epithelial
cells and therefore harbor a typical though heterogeneous structure with tumor cells forming com-
pact islets or nests surrounded by the stroma, enriched in ECM proteins, fibroblasts, blood vessels,
and immune cells. To unravel the relationship between tumor growth, ECM remodeling, stiffening,
and immune infiltration, we characterized the tumor structure and the mechanical properties of five
different preclinical models, recapitulating the structural heterogeneity of different carcinomas
(Supplementary file 1): a subcutaneous model of cholangiocarcinoma (EGI-1), a subcutaneous
(MET-1) and a transgenic model (MMTV-PyMT) of mouse breast carcinoma, and an orthotopic
(mPDAC) and a subcutaneous (KPC) model of mouse PDAC. A multiscale evaluation of the mechani-
cal properties of the tumors was performed. At the macroscale, we measured tumor stiffness during
tumor growth using SWE, a non-invasive imaging technique that allows the quantification and map-
ping of tumor stiffness (Figure 1A, Supplementary file 2). The presence of very stiff regions,
defined as areas with an elastic modulus > 40 kPa (Marangon et al., 2017), in the tumor was quanti-
fied together with the average stiffness of the tumor (Figure 1B, Supplementary file 2). At the
micron-scale, we evaluated tumor organization and fibrosis using hematoxylin–eosin–Safran (HES)
(Figure 1C) and Sirius Red staining (Supplementary file 2). Sirius Red is a highly specific stain for
collagen fibers that combined with polarizing microscopy allows differentiating thin collagen fibrils
from thick and densely packed collagen fibers (Rittié, 2017). Under polarized light, thin fibers show
a greenish-yellow birefringence, whilst thicker and densely packed fibers give an orange-red birefrin-
gence. By separating these two colors, it is possible to quantify the amount of thick and densely
packed fibers present in the tumor (Supplementary file 2). The fibrillar collagen network was deter-
mined using second-harmonic generation (SHG) imaging, which allows to analyze the architecture
and density of fibrillar collagen without having to use detection antibodies (Figure 1D,
Supplementary file 2).
In the EGI-1 cholangiocarcinoma model, tumor stiffening and tumor growth have a strong posi-
tive correlation (Figure 1A). The stiffness distribution is highly heterogeneous, presenting 20% of
stiff regions (>40 kPa) on average that goes up to 50–60% in tumors with higher volume. In terms of
architecture, the tumor and its extensive stroma compartment, occupying around 20% of the tumor,
are well separated. This is a typical trait of desmoplastic tumors and the model accurately reprodu-
ces the architecture of human cholangiocarcinoma. Its collagen network is characterized by long
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(85.9 ± 42.0 mm) and thick (7.4 ± 2.2 mm) collagen fibers that are densely packed (6% of the tumor)
(Figure 1D, Supplementary file 2).
The mouse PDAC KPC model (Hingorani et al., 2005) exhibits similar features to that of EGI-1. A
high positive correlation between tumor stiffness and volume, presenting over 20% of stiff regions at
high tumor volumes, was observed (Figure 1A). KPC tumors present typical segregation of ECM
and tumor nests, with a high proportion of stroma (~20%). However, the extension of the stromal
areas is lower than that of EGI-1 with higher intercalation with tumor islets. Its collagen network is
characterized by shorter (67.1 ± 35 mm) and thinner (4.4 ± 0.9 mm) collagen fibers than that of EGI-1
(Figure 1D, Supplementary file 2).
The spontaneous orthotopic murine breast cancer model MMTV-PyMT, although slower in its
growth as compared to subcutaneous tumors, also stiffens during tumor progression (Figure 1A).
However, there is a lower density of stiff regions (<16%). Of note, the fact that it is an orthotopic
Figure 1. Macroscopic and microscopic characterization of EGI-1, KPC, MMTV-PyMT, mPDAC, and MET-1 tumor models. (A) Tumor volume and tumor
mean stiffness relationship. Tumor volume was measured using a caliper or ultrasound, whilst tumor mean stiffness was measured using SWE. (B) The
percentage of stiff regions in relation to tumor volume. The presence of very stiff regions with an elastic modulus > 40 kPa was quantified using data
from the stiffness map extracted from the SWE images. (C) Comparison of the histological diversity within the tumor models. Representative images of
each tumor model (scale bar = 100 mm). (D) SHG images of the collagen network in each of the models at the end point of the experiment. Scale
bar = 20 mm. EGI-1 (n = 30 mice from three independent experiments); KPC (n = 34 mice from three independent experiments); MMTV-PyMT (n = 5
mice, 10 tumors per mouse from two independent experiments); mPDAC (n = 7 mice from two independent experiments); and MET-1 (n = 12 mice
from two independent experiments).
The online version of this article includes the following source data for figure 1:
Source data 1. Source data file for Figure 1.
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tumor in a genetic model that develops about 10 tumors limits the maximal tumor volume reached
for this analysis. Hence, we cannot compare this model with the other models at high tumor volumes
for ethical reasons. This spontaneous tumor model also presents a tumor islets-stroma structure, but
with a lower amount of stroma (~13%) as compared to EGI-1 and KPC models. The stroma is more
dispersed and intercalated with the tumor compartment. Collagen fibers are characterized for being
thin (3.6 ± 1.1 mm) and long (83 ± 41 mm), forming densely packed regions taking up to 4.8% of the
tumor.
The orthotopic murine PDAC (mPDAC) model has a very different profile compared to the other
models. The stroma takes up ~40% of the tumor (Figure 1C, Supplementary file 2) but without
clear spatial segregation of stromal and tumor compartments. The mPDAC collagen network is
made up of thin (3.5 ± 0.8 mm) and dispersed collagen fibers, which accounts for the lower presence
of densely packed collagen regions (2.7% of the tumor). The mean tumor stiffness is lower than that
of the other models, partly explained by the limits of the maximal tumor volume reached in this
orthotopic model (for ethical reasons) and partly by the collagen architecture. Tumor stiffness also
increases with tumor volume (Figure 1B) in line with previous studies performed in this model
(Gilles et al., 2016). Unlike the above-mentioned models that exhibit a high correlation between
stiffness and tumor growth, the mouse breast carcinoma MET-1 tumor model is characterized by low
tumor stiffness (Figure 1A), a limited stroma (~6%), the lack of tumor-islet/stroma organization, and
the presence of thin (3.2 ± 0.9 mm) and dispersed collagen fibers (Figure 1D, Supplementary file 2).
In human breast cancer, a significant correlation between tumor stiffness and tumor size was
demonstrated (Evans et al., 2012; Song et al., 2018). Here, our analysis enabled us to confirm such
correlation in different mouse tumor models covering three types of carcinomas. In addition, we
show a correlation between tumor stiffness measured non-invasively with collagen accumulation
associated with a segregated architecture of thick and densely packed collagen fibers (Sirius red
positive) surrounding tumor nests. In contrast, tumors with an entangled and thin mesh of collagen
fibers present lower rigidity despite overall high collagen content. Particularly the appearance of stiff
regions > 40 kPa is seen as a physical biomarker of intratumor heterogeneity and ECM segregation.
This analysis maps out potentially relevant preclinical tumor models, which might reproduce the
diverse fibrotic evolutions of human breast, pancreatic, and bile duct tumors and their architecture
heterogeneity.
LOX modulates tumor stiffness and the ECM organization
The panel of tumor stroma structures reported above allows us to investigate the direct effects of
ECM modulating agents in situations mimicking the heterogeneity observed in human carcinoma.
Thus, we sought to determine whether beta-aminopropionitrile (BAPN), an inhibitor for LOX enzy-
matic activity, could modulate tumors’ mechanical properties in concert with the stroma architecture
(Levental et al., 2009). For these experiments, BAPN was administered in the drinking water of
mice upon tumor cell implantation and until their sacrifice for most models, except for the MMTV-
PyMT model that was treated approximately at the time that tumors start to spontaneously develop.
LOX stabilizes collagen fibers by enzymatic reactions that culminate in the formation of trivalent
mature crosslinks including pyridinoline (PYD) and deoxypyridinoline (DPD) (Yamauchi et al., 2018).
PYD and DPD have an intrinsic fluorescence (Richards-Kortum and Sevick-Muraca, 1996), which
can be measured by two-photon microscopy (Ex 720 nm, Em 400 nm) on tissue sections
(Marturano et al., 2014). Here, we adopted a similar strategy and assessed these two LOX-gener-
ated crosslinks in tumor slices from control and BAPN-treated KPC-bearing mice. Our data indicate
that the average fluorescence signals of PYD and DPD, measured in SHG-positive regions, were sig-
nificantly decreased in BAPN as compared to control conditions (Figure 2—figure supplement 1).
These results suggest that BAPN specifically blocks LOX enzymatic activity. We then examined the
effect of LOX inhibition on tumor stiffness (Figure 2A,C) and on the presence of stiff regions
(Figure 2B). Results show that all models, except for MET-1, undergo a reduction in mean stiffness
when LOX is inhibited. EGI-1 and KPC models both show the most striking differences (Figure 2A,
C). Changes are mainly perceived at late stages of tumor developments since, in these models,
tumor stiffness is positively correlated with tumor growth. In the MMTV-PyMT model, however, sig-
nificant differences were noted throughout the development of the tumor. For the mPDAC model,
tumor stiffness was only evaluated at the end of the BAPN treatment. A significant decrease in mean
tumor stiffness is seen in BAPN-treated mPDAC tumors.
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Figure 2. Effect of LOX inhibition on tumor stiffness and tumor stroma organization in EGI-1, KPC, MMTV-PyMT, and mPDAC tumor models. (A) Tumor
stiffness measured by SWE in control and BAPN-treated (LOX inhibitor) tumors in relation to tumor volume for EGI-1, MMTV-PyMT, and KPC tumor
models. For the mPDAC tumor model, stiffness was only measured at the endpoint of the experiment (*p-value<0.05, **p-value<0.01, ***p-value<0.001
Student’s t-test). (B) Percentage of tumor area with stiffness > 40 kPa at three different time points in the late stages of tumor development. (C)
Illustrative examples of SWE images of each on the tumors at the last time point of the experiment (EGI-1 – day 30, KPC – day 41, MMTV-PyMT – day
55, mPDAC – day 21). EGI-1 (n = 30 mice/group from three independent experiments); KPC (n = 34 mice/group from three independent experiments);
MMTV-PyMT (n = 5 mice/group, 10 tumors per mouse from two independent experiments); mPDAC (n = 7 mice/group from two independent
experiments), and MET-1 (n = 12 mice/group from two independent experiments).
The online version of this article includes the following source data and figure supplement(s) for figure 2:
Source data 1. Source data file for Figure 2.
Figure supplement 1. Two-photon imaging analysis of collagen crosslink density from control and BAPN-treated conditions.
Figure supplement 1—source data 1. Source data file for Figure 2—figure supplement 1.
Figure supplement 2. Effect of LOX inhibition in EGI-1 tumor model.
Figure supplement 2—source data 1. Source data file for Figure 2—figure supplement 2.
Figure supplement 3. Effect of LOX inhibition in KPC tumor model.
Figure supplement 3—source data 1. Source data for Figure 2—figure supplement 3..
Figure supplement 4. Effect of LOX inhibition in MMTV-PyMT tumor model.
Figure supplement 4—source data 1. Source data file for Figure 2—figure supplement 4.
Figure supplement 5. Effect of LOX inhibition in mPDAC tumor model.
Figure 2 continued on next page
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Notably, BAPN treatment did not affect tumor growth in most models (Figure 2—figure supple-
ments 2A–6A), except for mPDAC (Figure 2—figure supplement 5A). To verify that the variation in
tumor stiffness was not due to a difference in tumor volume, the mean tumor stiffness of control and
treated mice were compared at different tumor volumes (Figure 2—figure supplements 2C–6C). In
both KPC and EGI-1 tumors, a clear difference in mean tumor stiffness can be seen in tumors with a
volume > 400 mm3 (Figure 2—figure supplements 2C–3C).
We also explored whether the presence and proportion of stiff regions was reduced when LOX
was inhibited (Figure 2B). The percentage of control tumor area with a mean stiffness > 40 kPa
increased with time (and with tumor volume) within the non-treated tumor indicating that there is
not only an increase of overall mean stiffness but also an increase of the heterogeneity of stiff
regions. However, this percentage was significantly reduced in BAPN-treated tumors with marked
differences observed in the KPC model and to a lesser extent in EGI-1 and MMTV-PyMT models. In
mPDAC, BAPN-treated tumors did not display stiff regions (Figure 2—figure supplement 5B–D).
The only model that does not respond to LOX inhibition by stiffness reduction is MET-1 (Figure 2—
figure supplement 6B–C), in line with our previous data showing an absence of tumor stiffening dur-
ing tumor growth. Overall, our results clearly illustrate: (1) the heterogeneity of tumor response to
an ECM-targeting agent, (2) the potential of non-invasive SWE elastography to measure a macro-
scopic physical marker – stiffness – that predicts this response.
Given the effects of LOX inhibition at a macro scale, we decided to delve into the changes
induced at the level of the collagen fiber network through an in-depth quantitative evaluation of col-
lagen fiber width (Figure 3A), orientation (Figure 3B,C), curvature (Figure 3D), and the presence of
regions with thick and densely packed fibers (Figure 3E).
A significant reduction of collagen fiber width distribution was observed in EGI-1, KPC, and
mPDAC models, whilst fibers in the MMTV-PyMT tumor model did not display a significant change
in their width (Figure 3A). The most substantial difference was seen in the EGI-1 model, where colla-
gen fiber width was decreased by 9.4% on average (6.7 mm versus 7.4 mm). Changes in mPDAC and
KPC were less pronounced, with a reduction of 4.4% and 5%, respectively (Supplementary file 3).
The inhibition of LOX did not affect collagen fiber length in any of the models (Supplementary file
3).
We next assessed the orientation and linearization of collagen fibers in control and BAPN-treated
animals. In general, the collagen fibers in normal tissues are typically curly and anisotropic in contrast
to the situation observed in progressing tumors in which many of the fibers progressively thicken
and linearize. Collagen fiber orientation was described as the coefficient of variation (CV) of the
angle for all fibers, the smaller the CV is, the more aligned the fibers are. Fibers in non-treated
tumors remained mainly oriented in one dominant direction (Figure 3B, C, and F) with a CV from
1.85 to 0.5 consistent with previous findings (Li et al., 2019). LOX inhibition tends to disrupt the
alignment of collagen fibers, meaning that they were more dispersed and oriented in different direc-
tions with increased CV as compared to control conditions. The most significant effects were seen in
KPC and mPDAC models.
Collagen fibers in tumors are characterized as being linear and reticulated due to the high level
of deposition and posttranslational crosslinking. This physical restructuration of collagen progres-
sively stiffness the ECM (Egeblad et al., 2010). The level of collagen linearization was quantified by
measuring the curvature ratio of the fibers. The curvature ratio of control tumors for all models was
close to one meaning that the collagen fibers were fully linearized. In contrast, LOX inhibition
severely affected fiber curvature, as there was a reversion of the fibers linearization resulting in less
linear and wavier fibers in all models (Figure 3D,F).
Finally, LOX inhibition also significantly decreased the surface covered by thick and densely
packed collagen fibers in EGI-1, KPC, and MMTV-PyMT model (Figure 3E, Figure 3—figure
Figure 2 continued
Figure supplement 5—source data 1. Source data file for Figure 2—figure supplement 5.
Figure supplement 6. Effect of LOX inhibition in MET-1 tumor model.
Figure supplement 6—source data 1. Source data file for Figure 2—figure supplement 6.
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Figure 3. Effect of LOX inhibition on ECM architecture in EGI-1, KPC, MMTV-PyMT, and mPDAC tumor models. (A) Collagen fiber width distribution
measured from SHG images (***p-value<0.001, Student’s t-test, 50–70 images/tumor, n = 3 mice/group from three independent experiments). (B) Fiber
orientation defined by the coefficient of variation (CV) (***p-value<0.001, Student’s t-test, 40–50 images/tumor, n = 3 mice/group from three
independent experiments). (C) Representative example of fiber orientation distribution. (D) Collagen fiber curvature defined by the curvature ratio
Figure 3 continued on next page
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supplement 1), correlating with the significant decrease in average tumor stiffness and in the pro-
portion of stiff areas measured in vivo.
In vivo stiffness imaging and ex vivo characterization of the ECM structure were completed by ex
vivo mechanical evaluation of isolated tissue samples with atomic force microscopy (AFM) nanome-
chanical measurements and plate shear rheometry at the tissue level in the KPC model. Figure 4
shows the mean values of storage modulus (G’) of control and BAPN-treated tumors. It can be noted
that tumors treated with BAPN were softer than control ones, with mean stiffness of 1.80 ± 0.51 kPa
compared to 4.15 ± 1.92 kPa for the control. These results are in line with SWE measurements in
vivo confirming a significant reduction in the mean stiffness of KPC tumors treated with a LOX inhibi-
tor. In contrast to bulk rheometry, AFM reveals the spatial heterogeneity of Young’s moduli at the
sub-cellular level measured on six controls (Figure 4—figure supplement 1) and six BAPN-treated
tumors (Figure 4—figure supplement 2). For each sample, high heterogeneity in tumor stiffness
can be observed, as previously seen in other types of solid tumors like breast cancer
Figure 3 continued
(***p-value<0.001, Student’s t-test, 40–50 images/tumor, n = 3 mice/group from three independent experiments). (E) Percentage of red-orange
birefringent fibers combining Red Sirius staining and polarized microscopy, orange-red fibers correspond to thick and packed regions (*p-value<0.05,
***p-value<0.001, Student’s t-test, 20–30 images/tumor, n = 3 mice/group from three independent experiments). (F) SHG images of collagen networks
in EGI-1, MMTV-PyMT, mPDAC, and KPC control and BAPN-treated tumors. Illustrative scheme indicating the changes in width, orientation and
curvature of collagen fibers induced by BAPN treatment. Scale bar = 50 mm. Images are representative of three experiments.
The online version of this article includes the following source data and figure supplement(s) for figure 3:
Source data 1. Source data file for Figure 3.
Figure supplement 1. Combination of Sirius Red staining and polarized microscopy.
Figure 4. Mechanical properties of the mouse pancreatic ductal adenocarcinoma KPC tumor model and effects of LOX inhibition. (A) Rheological
properties of tumor samples measured using a plate shear rheometer. Mean storage modulus (G’) for all control and BAPN-treated samples ± SD are
presented (for 5% sample compression). (B) The Young’s modulus values distributions obtained for all control and treated tumor samples using the
AFM indentation technique. Inset in (B) shows tissues’ Young’s modulus mean values ± standard deviation to highlight the difference between control
and BAPN tissues. Statistical significance was determined using a two-tailed Student’s t-test for overall values (***p-value<0.001, Student’s t-test, n = 6
tumors/group from three AFM experiments; *p-value<0.05, Student’s t-test, n = 5 tumors/group from three rheometer experiments).
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source data 1. Source data file for Figure 4.
Figure supplement 1. The distributions of Young’s moduli obtained for the control mouse pancreatic ductal adenocarcinoma.
Figure supplement 1—source data 1. Source data file for Figure 4—figure supplement 1.
Figure supplement 2. The distributions of Young’s moduli obtained for the BAPN-treated mouse pancreatic ductal adenocarcinoma.
Figure supplement 2—source data 1. Source data file for Figure 4—figure supplement 2.
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(Plodinec et al., 2012). AFM measurements indicated that treatment of mice with BAPN leads to a
narrower Young’s modulus distributions shifted to lower values of elastic modulus in comparison to
the control samples (mean Young’s modulus of 0.82 ± 1.58 kPa versus 1.70 ± 1.66 kPa, respectively)
(Figure 4B). This confirms that the high heterogeneity in local tissue mechanical properties of KPC
tumor can be reduced upon treatment with a LOX inhibitor. Both local and global measurements
confirm the normalization of tumor tissue mechanical properties mediated by LOX inhibition with a
drastic reduction in the linearized tightly packed collagen fibers that contribute to tumor stiffness
heterogeneity and global enhancement in non-treated KPC tumors.
Overall, our results demonstrate the rationale of targeting LOX enzymatic activity for normalizing
tumor mechanical properties and ECM structure (mostly collagen fibers compaction, segregation,
and linearity) in tumors exhibiting high tumor stiffness together with mechanical and structural
heterogeneity.
LOX inhibition increased intratumoral T cell migration and infiltration
Previous studies performed in our group have proved that the density and orientation of the ECM
can have an important impact on T cell behavior and their displacement in fresh human lung and
ovarian tumor slices (Salmon et al., 2012; Bougherara et al., 2015). Motile T cells were mainly
found in loose ECM stromal regions, whereas fibrotic areas were devoid of lymphocytes. Based on
this, we hypothesized that LOX-dependent tumor stiffness could consequently affect T cell migration
in tumors and eventually predict the T cell behavior in the various ECM environments. To test this,
we performed dynamic imaging of T cell migration on fresh tumor slices from mice treated or not
with BAPN. The tumor slice assay that we have established preserves the original tissue microenvi-
ronment and permits monitoring with confocal microscopy the behavior of either ex vivo purified
and plated T cells or endogenous T cells labeled with directly coupled fluorescent antibodies
(Peranzoni et al., 2018). EGI-1 is a xenografted tumor model, with implantation of human carcinoma
cells into immune-suppressed mice that lack resident T cells. Thus, in order to evaluate T cell migra-
tion in this model we isolated human peripheral blood T cells (PBT) and activated them in vitro. We
then added the activated PBT onto fresh tumor slices and analyzed their migration using real-time
confocal microscopy. As the MMTV-PyMT tumor model is poorly infiltrated in host T cells
(Guerin et al., 2019), we investigated the migration of exogenously purified murine-activated PBTs
in the same manner as for the human EGI-1 model. In both mPDAC and KPC mice tumor models,
resident tumor-infiltrating T lymphocytes were monitored after staining with directly coupled anti-
CD8 antibodies (Peranzoni et al., 2018). The three parameters analyzed to assess T cell migration
were cell migration speed (mean cell migration speed over 20 min), cell displacement (displacement
vector between starting and final position), and straightness (ratio of cell displacement to the total
length of the trajectory) of the migration trajectory (Figure 5 and Supplementary file 4).
In control untreated tumors, T cells migrated slowly with average velocities which were relatively
homogeneous in the different models except in the mPDAC model (Video 1). Average velocities
ranged from 2.3 mm/min in the EGI-1 model to 4.1 mm/min in the MMTV-PyMT model. These values
are in line with a number of studies including ours showing a poor migration of T cells in tumors as
compared to other organs (e.g. in lymph nodes) where T cells actively migrate (Peranzoni et al.,
2018). For example, the mean velocity of CD8 T cells in human lung tumors approaches 3 mm/min
(Peranzoni et al., 2018). Analysis of T cell track straightness gives indices close to 0.4 consistent
with previous reports on T cell displacements in tumors.
The mPDAC model differs from the others since T cells were almost static during the 20 min
recording (average speed of 1 mm/min and straightness of 0.1).
In every tested model, LOX inhibition resulted in an overall increase in T cell migration as com-
pared to control conditions (Figure 5, Supplementary file 4 and Video 2). However, different
parameters were altered in each model depending on the nature of the T cells that were monitored.
In EGI-1 BAPN-treated tumors, activated PBT cells displayed longer displacement lengths compared
to untreated tumors. This was also true for MMTV-PyMT tumors. Since activated PBT are not specific
to the tumor, the effects observed are due to LOX inhibition and not due to T cells engaging in sta-
ble conjugates with cancer cells through antigen recognition. In EGI-1 tumors, the trajectory straight-
ness of activated PBTs was also significantly increased upon LOX inhibition.
Effects of BAPN on the dynamics of endogenous T cells infiltrated into KPC and mPDAC tumors
were then evaluated (Figure 5 and Supplementary file 4). We found that in both models, LOX
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inhibition leads to an increase in the displacement of T cells with a fivefold increase in the mPDAC
model. In terms of cell speed, enhancements were observed only in the mPDAC model. Likewise,
the trajectory straightness was increased in mPDAC models, but not in KPC tumors. In addition, we
also evidenced an increased infiltration of resident T cells in KPC tumors when treated with BAPN. In
control conditions, an identical number of T cells (around 100 per mm2) were found in the stroma
and tumor cell regions. By comparison, BAPN treatment resulted in a threefold to fourfold increase
of CD8+ T cells in both the stroma and tumor islets (Figure 5—figure supplement 1).
Results reported in Figure 5 have been obtained with data pooled from all mice either treated or
not with BAPN. We decided to extend our analysis at the level of individual mouse and investigated
the relationship between T cell motility (speed and displacement) and mean stiffness of control and
BAPN-treated tumors. Our data indicate that T cell motility was inversely correlated to tumor stiff-
ness (Figure 6) in line with Figure 5. However, in three out of the four models tested this correlation
is different if one compares control and BAPN-treated tumors. In BAPN-treated tumors, there is a
clear inverse linear correlation between T cell migration speed and mean tumor stiffness as
Figure 5. Impact of LOX inhibition on T cell migration in EGI-1, MMTV-PyMT, mPDAC, and KPC tumor models. Migration of activated PBT plated onto
fresh tumor slices was analyzed in EGI-1 and MMTV-PyMT tumor model, whilst resident tumor-infiltrating T lymphocytes were analyzed in mPDAC and
KPC tumor model. Illustrative images of T cell migration tracks in EGI-1, MMTV-PyMT, mPDAC, and KPC tumor models. Tumor stroma (fibronectin) in
red, tumor cells (EpCAM in EGI-1, MMTV-PyMT, and KPC tumor models, CD44 in mPDAC tumor models), in blue and T cells (CD8 in mPDAC and KPC,
Calcein in MMTV-PyMT, and EGI-1 tumor models) in green. Tracks are color-coded to illustrate track displacement. Scale bar = 100 mm. T cell migration
speed, T cell displacement, and trajectory straightness in all tumor models. ***p-value>0.001, p-value>0.05, Student’s t-test. Results are shown as
mean ± SD.
The online version of this article includes the following source data and figure supplement(s) for figure 5:
Source data 1. Source data file for Figure 5.
Figure supplement 1. BAPN treatment induces an increased infiltration of effector CD8+T cells in KPC tumors.
Figure supplement 1—source data 1. Source data file for Figure 5—figure supplement 1.
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evidenced by a steep slope. In comparison, such
correlation is less pronounced in control stiff
tumors. Similar results were observed when com-
paring T cell displacement and mean tumor stiff-
ness. These results suggest that above a stiffness
threshold that depends on the model, T cells are
mostly arrested. In contrast, as tumor stiffness
decreased by inhibition of LOX, T cell migration
was restored. Thus, T cell motility is highly influ-
enced by small variations in the stiffness of softer
tumors as is the case when LOX’s activity is
inhibited.
Overall, these results suggest that the exces-
sive accumulation and linearization of collagen in
ECM limits T cell migration within several rigid
tumors with desmoplastic evolution and that
LOX-inhibiting BAPN treatment can both reverse
tumor stiffening and improve T cell infiltration
and migration to tumor cells. We also identify
SWE tissue stiffness as a predictive physical
marker of T cell motility and infiltration in desmo-
plastic tumors.
LOX inhibition improves response to anti-PD-1 therapy
Even though the inhibition of LOX was followed by an increase in CD8 T cell number and migration,
this finding was not accompanied by major effects on tumor growth in four of the five tumor models
tested (Figure 2—figure supplements 2–6). In different settings, an increase in intratumoral T cell
motility is not sufficient to reduce tumor growth if T cells are still impaired in their capacity to
respond to tumor antigens (Peranzoni et al., 2018). Consequently, we decided to assess whether
LOX inhibition could improve the response to immune checkpoint inhibitors. The KPC model was
chosen for these experiments as tumors are stiff, respond to LOX inhibition in terms of ECM normali-
zation, and are infiltrated with T cells. KPC tumor-bearing mice were treated with BAPN combined
with anti-PD-1 antibodies. Mice were treated or not with BAPN from tumor cell injection up to their
sacrifice and were treated with anti-PD-1 antibodies when the tumor volume was around 80–150
mm3. At this point, the mice received four doses i.p. injection of anti-PD-1 or isotype control anti-
body at 4 days intervals (i.p. injection). Unlike
BAPN, PD-1 blockade did not affect tumor stiff-
ness (Figure 7—figure supplement 1A,B) nor
collagen organization including fiber orientation
and curvature (Figure 7—figure supplement
1C–E). Moreover, the combination therapy was
similar to that of BAPN alone on all of these
parameters. We then investigated the conse-
quences of these treatments on tumor growth.
As shown in Figure 7A, while treatment with sin-
gle agents alone only shows non-significant
reduction in tumor growth, the combination of
BAPN with the checkpoint inhibitor significantly
delays tumor progression. We then profiled the
immune cell population in these tumors using
flow cytometry and a gating strategy shown in
Figure 7—figure supplement 2. We found that
BAPN treatment alone significantly decreases
the number of polymorphonuclear neutrophils
(Figure 7B), but increases the presence of
MHCII+ tumor-associated macrophages (TAMs)
Video 1. T cell migration in the control EGI-1 tumor
model. The slices stained with calcein for the T cells
(green), anti-EpCAM (blue), anti-fibronectin (red) were
imaged with a spinning disk confocal microscope.
Tracks are color-coded according to T cell
displacement length. Frame interval 30 s. The
animations represent 3D reconstructions of sequential z
series. A still image is shown in Supplementary file 4.
https://elifesciences.org/articles/58688#video1
Video 2. T cell migration in the LOX inhibited EGI-1
tumor model. The slices stained with calcein for the T
cells (green), anti-EpCAM (blue), and anti-fibronectin
(red) were imaged with a spinning disk confocal
microscope. Tracks are color-coded according to T cell
displacement length. Frame interval 30 s. The
animations represent 3D reconstructions of sequential z
series. A still image is shown in Supplementary file 4.
https://elifesciences.org/articles/58688#video2
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(Figure 7C), while the combination therapy expanded the percentage of GrzmB CD8+ T cells
(Figure 7D) and the ratio of CD8+ to Treg cells (Figure 7E). We also analyzed the amount of cyto-
kines in supernatants of whole-tumor slices derived from these experiments. Results show that the
combination therapy led to an increase in TNFa and RANTES, supporting further the increase of T
cell activation and infiltration and activation in this condition (Figure 7F–G). In both BAPN and
BAPN combined with anti-PD-1 conditions, we observed an increase of GrzmB+ levels compared to
the control condition (Figure 7H). Of note, BAPN and anti-PD-1 alone also showed a similar ten-
dency for an increase in TNFa and RANTES, which prompted us to study the consequences of these
treatments on the intratumoral T cell motility. Consistent with the data in Figure 5, LOX inhibition
leads to an increase in T cell displacement within the KPC tumor (Figure 7—figure supplement 1F).
We also found that PD-1 blockade alone produced a similar increase in T cell motility, whereas the
combination therapy showed the same effects as treatments alone (Figure 7—figure supplement
1F).
Overall, while ECM and stiffness normalization achieved through LOX inhibition increases T cell
infiltration and migration, this strategy also improves the efficacy of anti-PD-1 blockade on tumor
growth.
Discussion
Despite the success of targeting the stromal compartment in tumors (Mariathasan et al., 2018;
Salmon et al., 2012; Caruana et al., 2015; Chen et al., 2019; Incio et al., 2015; Elahi-
Gedwillo et al., 2019), in particular tumor ECM, there are still a series of challenges that remain to
be addressed. In the first part of this study, we tackle two of these challenges. One of them is find-
ing ways to accurately assess the architecture of the stroma. In this paper, we propose a thorough
analysis combining non-invasive imaging techniques for a macroscopic characterization of tumor
stiffness with advanced microscopy techniques to elucidate the collagen network structure, one of
the most important components of the tumor ECM. Previous studies had already explored the link
between tumor stiffness and collagen architecture (Venkatesh et al., 2008; Samani et al., 2007;
Figure 6. Correlation between mean tumor stiffness and T cell migration parameters in EGI-1, KPC, MMTV-PyMT, and mPDAC tumor models. (A)
Correlation between mean tumor stiffness and mean T cell velocity. (B) Correlation between mean tumor stiffness and mean T cell displacement.
Averaged T cell velocity and displacement were calculated from at least 50 individual cells. Each point represents values from an individual mouse. EGI-
1 (n = 8 mice/group); KPC (n = 4 mice/group); MMTV-PyMT (n = 6–7 mice/group); and mPDAC (n = 4 mice/group) from two to three experiments.
The online version of this article includes the following source data for figure 6:
Source data 1. Source data file for Figure 6.
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Mieulet et al., 2021). Here, we provide novel insights about this relationship through a multiscale
analysis performed in several preclinical mouse models of pancreatic, breast, and bile duct carcino-
mas, presenting different ECM organizations and thus covering the heterogeneity found in cancer
patients. This allowed us to extract mechanical and structural reference values and allowed us to
later evaluate the effect of an ECM-targeted therapy. Such an approach could be translated to
patients given the availability of SWE techniques that could be correlated to histological observa-
tions of the tumor microenvironment.
Accurately modeling tumor complexity and heterogeneity found in patients’ tumors using a single
preclinical model is a real challenge. In the first place, many preclinical models do not always repro-
duce the carcinoma structure found in their respective human tumors. Another important feature of
human solid tumors, often absent in mouse tumor models, is their considerable higher stiffness com-
pared to their neighboring healthy tissues, which is highly correlated with cancer progression and
metastasis (Evans et al., 2012; Song et al., 2018; Yoo et al., 2020; Evans et al., 2018). These two
features can often be found in human xenograft models that, on the other hand, are not suitable to
study immune reactions. In this study, we have set up and characterized five different solid tumor
models covering three types of carcinomas that differentiate in terms of tumor-stroma organization,
tumor stiffness, collagen structure, and T cell infiltration. The xenotransplanted cholangiocarcinoma
Figure 7. LOX inhibition increases the efficiency of anti-PD-1 therapy in KPC tumor model. (A) Tumor volume fold change after combination therapy of
BAPN with anti-PD-1. n = 8 mice/group from two independent experiments. (B) CD11b+, Ly6G+, Ly6C+PMN/mg of tissue. (C) CD64+F4/80+MHCII
+TAMs/mg of tissue. (D) CD8+ T cells/mg tissue. (E) CD8+ to FoxP3+Treg ratio. (F–H) Multiplex analysis of inflammatory chemokines (TNFa, RANTES,
and GrzmB) produced by fresh KPC tumor slices kept in culture for 18 hr (*** p-value<0.001, * p-value<0.05, one-way ANOVA, Krustal Walis, n = 8 slices
per condition from two independent experiments).
The online version of this article includes the following source data and figure supplement(s) for figure 7:
Source data 1. Source data file for Figure 7.
Figure supplement 1. Effect of LOX inhibition and anti-PD1 therapy on tumor stiffness, stroma organization and T cell motility in KPC tumors.
Figure supplement 1—source data 1. Source data file for Figure 7-figure supplement 1.
Figure supplement 2. FACS sequential gating strategies.
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tumor model (EGI-1) has an extensive stromal compartment well separated from tumor islets, which
is a typical feature of desmoplastic tumors. Likewise, the KPC tumor model has also typical segrega-
tion of ECM and tumor nests and reproduces many of the key features observed in human PDAC
including a stiff tumor and an exclusion of T cells from tumor islets. The orthotopic mPDAC model
also contains very few T cells, although tumors are less stiff than the previous two models. The spon-
taneous MMTV-PyMT model is relevant with respect to human breast carcinoma as tumors devel-
oped in four stages (hyperplasia, adenoma/mammary intraepithelial neoplasia, and early and late
carcinoma) (Lin et al., 2003). As a result, the architecture of MMTV-PyMT tumors resembles that of
human breast cancers. On the other hand, the MET-1 model only contains thin stromal compart-
ments and unlike the previous models, tumors are not very stiff, probably reflecting a specific sub-
type of human breast cancers. Once the tumor structure and mechanical properties of each model
were characterized, an ECM-targeting therapy dependent on LOX inhibition with BAPN was tested.
Previous studies performed by Levantal et al. in a spontaneous mouse model of breast carcinoma
showed that LOX inhibition induces structural changes in the collagen network (Levental et al.,
2009). Here, we confirm and extend these results in other models and provide multiscale insights
about different effects of LOX inhibition from model to model, including stiffness measurements at
the tissue level. Whilst for cholangiocarcinoma (EGI-1) and pancreatic adenocarcinoma models (KPC
and mPDAC), LOX inhibition drastically decreases tumor stiffness, this effect is less marked in the
breast adenocarcinoma model (MMTV-PyMT). Although collagen fiber curvature was affected in all
models, changes in fiber orientation were only significant in KPC and mPDAC models. These
changes can be explained by the fact that the tumor microenvironment and thus the basal collagen
structure in each tumor model is different; hence, the inhibition of collagen crosslinking modifies the
tumor collagen network to different extents. This emphasizes the need of developing reliable diag-
nostic markers, such as SWE stiffness mapping, based on a clear understanding of the tumor colla-
gen network, in order to predict the response to ECM-targeting strategies.
In this study, LOX inhibition was performed in a preventive setting. We assume that it is during
early tumor stages and the construction of fibrous stroma that LOX activity is the highest. In estab-
lished tumors, with stroma having a significant level of crosslinked collagen, LOX inhibition would
have a more marginal effect. Although not dealing with anti-PD-1 treatment, several articles are con-
sistent with the notion that LOX inhibition is more effective in early tumor stages (Nilsson et al.,
2016; Miller et al., 2015). For example, blocking LOX in combination with gemcitabine reduced
metastases and increased survival of the mice when treatment was started in the early stages of the
disease, but not at later stages (Miller et al., 2015).
It is well established that the number of T cells found within a tumor as well as their ability to
migrate and reach cancer cells is key for an effective antitumoral response. These last few years a lot
of efforts have been made in identifying cells and factors controlling the migration of T cells within
tumors. The notion that prevailed is that growing tumors are composed of cells and factors, such as
macrophages and hypoxia, hostile for T cells to migrate (Peranzoni et al., 2018; Manaster et al.,
2019). The importance of the ECM in controlling the distribution and migration of T cells in tumors
has also emerged. In human lung and ovarian tumors we found that T cells preferentially accumulate
and migrate in stromal regions that exhibited a loose matrix architecture but not in dense regions
(Salmon et al., 2012; Bougherara et al., 2015). Likewise, in aged skin, dermal fibroblasts harbor a
phenotype similar to CAFs and produce ECM matrices that limit T cell displacements (Kaur et al.,
2019). However, in triple-negative breast cancers and in pancreatic tumors, T cells were still found in
dense networks of collagen fibers (Li et al., 2019; Carstens et al., 2017). Since most of the afore-
mentioned studies were correlative, we decided in this study to specifically alter the ECM network
by LOX inhibition and investigated the consequences on T cell motile behavior. Our results con-
firmed the importance of the ECM and tissue stiffness in controlling the migration of T cells in
tumors. In particular, enhancements of T cell displacements were noticed in all tumor models under
LOX inhibition. When we extended our analysis at the level of the individual mouse, we found that T
cell intratumoral motility was inversely correlated to tumor stiffness as measured non-invasively using
SWE (Figure 6), and this was true in all tested models. However, this relationship is not linear. In
most models, T cells strongly decelerate when a threshold in stiffness is reached. In soft tumors such
as those induced by LOX inhibition, T cells manage to migrate. Conversely, in stiff non-treated con-
trol tumors, T cell migration is impeded. These data fit well with results obtained in vitro in a range
of 3D collagen matrices showing that T lymphocytes have the ability to adapt their morphology to
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the structure of the tissue up to a certain limit (Wolf et al., 2013). In dense collagen matrices, T cell
motility is halted. Our analysis supports the idea that elastography measurements could provide
valuable companion markers to evaluate the need for anti-stromal strategy in order to normalize
tumor stiffness and consequently improve T cell migration.
In this study, we did not take into consideration the possible effects of LOX inhibition on other
determinants that could either positively or negatively regulate T cell migration. Along with tumor
ECM, other cells and factors play important roles in controlling T cell migration. Hence, PD-1 block-
ade that does not affect collagen structure increases T cell migration within tumors (Figure 7—fig-
ure supplement 1F). It is well established that anti-PD-1 treatment is associated with the production
of IFNg and inflammatory chemokines (e.g. CXCL10) that are presumably responsible for enhancing
T cell motility in tumors (Peng et al., 2012). A number of studies have shown that fibrotic tumors
are, at the same time, enriched in cells and factors that are known to impede T cells from migrating
(e.g. hypoxia and tumor-associated macrophages) (Manaster et al., 2019; Maller et al., 2021;
Deligne et al., 2020). Therefore, a reduction in ECM content might normalize the tumor stroma ren-
dering it more prone to stimulate T cell migration. The data in Figure 7 showing a decrease in PMN
and Treg and an increase in MHC class II + macrophages upon BAPN treatment support this
assumption.
As for possible effects of LOX inhibition on tumor blood vessels, previous studies have reported
reduced angiogenesis after LOX and LOX-like protein inhibition and an increased perfused vessel
density in the case of overexpression of LOX (Baker et al., 2013; Zaffryar-Eilot et al., 2013). This
could partly explain why we observe a significant increase in T cell infiltration in KPC tumors upon
BAPN treatment. However, other recent studies argue the opposite as an increase in collagen cross-
linking and matrix stiffness resulted in an increase in angiogenic sprouting. Conversely, the inhibition
of collagen crosslinking in tumors resulted in reduced vascular density and permeability
(Bordeleau et al., 2017).
Given the low efficacy of T cell-based immunotherapies in solid tumors, any method to increase
its effect on tumor regression is of interest. With the exception of desmoplastic melanomas
(Eroglu et al., 2018), features of wound healing and fibrosis are usually detrimental to anti-PD-1
responses (Hugo et al., 2016). Accordingly, a number of anti-fibrotic strategies have been recently
implemented in combination with immune checkpoint inhibitors (Jiang et al., 2017). One of the
most promising targets appears to be TGFb. In preclinical mouse tumor models, TGFb inhibition
with immune checkpoint blockade induces complete and durable responses in otherwise unrespon-
sive tumors (Mariathasan et al., 2018; Tauriello et al., 2018). However, due to TGFb pleiotropic
effects, concerns regarding the blockade of this cytokine arose.
Our study indicates that LOX represents another valuable target as its inhibition in the trans-
planted KPC model increases the efficacy of anti-PD-1 treatment, while monotherapy with either
agent alone is ineffective. Moreover, the combination treatment was associated with a tumor micro-
environment shifted toward antitumoral effector cells and components, whereas immunosuppressive
cells were reduced.
Although the clinical use of BAPN has been impeded by concerns regarding toxicities, other strat-
egies to inhibit LOX in cancer and fibrotic disease patients are currently ongoing (Lampi and Rein-
hart-King, 2018). Our work confirms LOX as a molecular target to improve T cell migration
dynamics as well as to ameliorate the immunosuppressive microenvironment. It paves the way for
clinical trials combining LOX inhibitors with PD-1/PD-L1 blockade, possibly in biomarker-selected
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Cell culture
The KPC cell line was derived from a pancreatic tumor obtained from KrasLSL_G12D, Trp53R172H/+
mice (C57BL/6 background, a generous gift from Corinne Bousquet, Université Toulouse III).
The pancreatic cancer cell line mPDAC was derived from a tumor obtained from KrasLSL_G12D,
Trp53R172H/+, Cdkn2a-/+ mice (obtained from Douglas Hanahan, Swiss Institute for Experimental
Cancer Research).
The MET-1 cell line was derived from a mammary carcinoma in FVB/N-Tg (MMTV-PymT)
(obtained from Robert Cardiff, the University of California, Davis; Borowsky et al., 2005).
EGI-1 cells, derived from the extrahepatic biliary tract, were obtained from the German Collection
of Microorganisms and Cell Cultures (DSMZ, Germany).
mPDAC and KPC cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS),
penicillin/streptomycin, L-glucose, and sodium pyruvate (Gibco). EGI-1 cells were cultured in DMEM
supplemented with 1 g/L glucose, 10 mmol/L HEPES, 10% FBS, antibiotics (100 UI/mL penicillin and
100 mg/mL streptomycin), and antimycotic (0.25 mg/mL amphotericin B) (Invitrogen).
Each cell line was thawed from lab-frozen stock which were generated from early passages and
utilized for each experiment within 4 weeks culture. All the cell lines utilized were mycoplasma free
determined by qPCR analysis.
Human CD8+ T cells were isolated from cytapheresis rings (obtained from Establissement Fran-
çais du Sang) using EasySep Human CD8+ T Cell Isolation Kit (Stem Cell Technologies), following
manufacturer’s protocol. They were cultured in RPMI supplemented with 3% Human AB serum, T
cell TransAct (Miltenyi Biotech), 155 U/mL of human IL-7 (Miltenyi Biotec), and 290 U/mL of human
IL-15 (Miltenyi Biotech). Two to three days after activation, the cell culture media was changed using
the same recipe without TransAct. At day 7 after activation, T cells were used for migration
experiments.
Mouse CD8+ T cells were isolated from FVB mouse spleen and lymph nodes using CD8a+ T Cell
Isolation Kit (Miltenyi Biotech) following the manufacturer’s protocol. Isolated T cells were activated
using the Dynabeads Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activation (Thermo
Fischer) following the manufacturer’s protocol. On 7 seven after activation, T cells were used for
migration experiments.
In vivo studies
Mouse tumor models used in this study were as follows:
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EGI-1 subcutaneous model
2  106 cells suspended in 60 mL of PBS were mixed with 60 mL of Matrigel growth factor reduced
(Corning) and implanted subcutaneously into the flank of 5-week-old female NMRI-nu (nu/nu) mice
(Envigo, France).
KPC subcutaneous model
3  106 cells suspended in 50 mL of PBS were mixed with 50 mL of Matrigel growth factor reduced
(Corning) and implanted subcutaneously into the flank of 6-week-old female C57BL/6J mice (Janvier,
France).
MET-1 subcutaneous model
106 cells suspended in 50 mL of PBS were injected subcutaneously into the flank of a 6-week-old
female FVB mouse (Janvier France).
MMTV-PyMT model
FVB MMTV-PyMT model is maintained at the Cochin Institute specific-pathogen-free- animal facility
in accordance with the University Paris Descartes ethical guidelines.
mPDAC orthotopic model
103 cells suspended in 50 mL of PBS were injected orthotopically in the pancreas of 6-week-old FVB/
n mice (Janvier, France). Tumor growth was followed through ultrasound imaging using a VEVO2100
(Visualsonics).
Tumor growth was followed with a caliper, and tumor volume (V) was calculated as follows: xeno-
graft volume = (xy2)/2 where x is the longest and y, the shortest of two perpendicular diameters.
For LOX inhibition, animals were treated with BAPN (3 mg/mL, Sigma) in the drinking water,
which was changed twice per week. In all implantable models (KPC, mPDAC, MET-1, and EGI-1), ani-
mals were treated from the day of the tumor implantation until the end of the study. For the MMTV-
PyMT model, animals were treated at 10 weeks of age, approximately the moment the tumor
started developing.
Experiments combining LOX inhibition and anti-PD1 were conducted in the KPC model. Four i.p.
injections of 200 mg of anti–PD-1 antibody (RMP1-14 clone; BioXcell) or isotype control (rat IgG2a;
BioXCell) were started when tumors reached 80–100 mm3 size. Injections were performed every 4
days.
All animal experiments were performed in agreement with institutional animal use and care regu-
lations after approval by the animal experimentation ethics committee of Paris Descartes University
(CEEA 34, 16–063).
Shear wave elastography
SWE measurements were performed every 3–4 days during the entire follow-up of the tumor
growth. Images were acquired with the ultrasound device Aixplorer (SuperSonic Imagine, Aix-en-
Provence, France) using a 15 MHz superficial probe dedicated to research (256 elements, 0.125 mm
pitch).
The mice were anesthetized with 2% isoflurane, and their body temperature was maintained at a
physiological level using a heating plate. B-mode images and SWE images were acquired simulta-
neously. The B-mode image allowed us to manually determine the region of interest (ROI) corre-
sponding to the tumor contours. SWE mode was performed using the penetration mode with a
color scale ranging from 0 (blue) to 40 kPa (red); this cut-off was chosen based on the results from a
previous study performed by our group (Marangon et al., 2017). The area, the diameter, and a set
of stiffness values (mean, minimum, maximum, and standard deviation) were recorded for the ROI as
previously defined. SWE images were also analyzed using an in-house MATLAB code to recover the
stiffness map. Once the stiffness map was recovered, the percentage of pixels within the ROI with
stiffness values > 40 kPa with respect to the total number of pixels in the region was calculated in
order to analyze the percentage of stiff regions. The normalized tumor stiffness was calculated by
normalizing each time point measurement with that of the initial time point (Stiffness tn/Stiffness t0).
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Tumor slice imaging
Tumor slices were prepared following the protocol described previously (Peranzoni et al., 2018).
Briefly, samples were embedded in 5% low-gelling-temperature agarose (type VII-A; Sigma-Aldrich)
prepared in PBS. Slices (350 mm) were cut with a vibratome (VT 1000S; Leica) in a bath of ice-cold
PBS.
To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled
with CellTrace Calcein red-orange dye (ThermoFischer). Briefly, T cells were incubated with 125 nM
Calcein in HBSS solution for 10 min at 37˚C. The staining reaction was stopped by adding cold HBSS
supplemented 2% SAB. Cells were then pelleted and diluted to an appropriate concentration in phe-
nol red-free RPMI media. 2  105 cells suspended in 50 mL of phenol red-free RPMI media and
added on 350 mm tumor slices placed on top of 0.4 mm organotypic culture inserts (Millicell; Milli-
pore) in 35 mm Petri dishes containing 1.1 mL RPMI 1640 without Phenol Red. The tumor slices were
then incubated for 30 min at 37˚C and 5% CO2. The slices were then washed to remove all cells that
had not infiltrated the slice and stained for 15 min at 37˚C with the following antibodies: BV421–anti-
human EpCAM (9C4 clone; BioLegend) and anti-human/mouse fibronectin at 10 mg/mL (HFN7.1
clone; Acris antibodies). The same protocol was followed to evaluate T cell migration in MMTV-
PyMT cells except that activated murine CD8+ T cells were used.
To evaluate resident T cell migration in KPC and mPDAC model, tumor slices were then trans-
ferred to 0.4 mm organotypic culture inserts (Millicell; Millipore) in 35 mm Petri dishes containing 1.1
mL phenol red-free RPMI media. Live vibratome sections were stained with BV421 anti-mouse
EpCAM (G8.8 clone; BD Biosciences), PerCP-e710 anti-mouse CD8a (53–6.7 clone, eBioscience), PE
anti-podoplanin (8.1.1 clone; BioLegend), and anti-human/mouse fibronectin (HFN7.1 clone; Novus
Biologicals).
T cells were imaged with a DM500B upright microscope equipped with an upright spinning disk
confocal microscope (Leica) equipped with a 37˚C thermostatic chamber. For dynamic imaging,
tumor slices were secured with a stainless steel slice anchor (Warner Instruments) and perfused at a
rate of 0.8 mL/min with a solution of RPMI without Phenol Red, bubbled with 95% O2 and 5% CO2.
Ten minutes later, images from a first microscopic field were acquired with a 25 water immersion
objective (20/0.95 N.A.; Olympus). For four-dimensional analysis of cell migration, stacks of 10–12
sections (z step = 5 mm) were acquired every 30 s for 20 min at depths up to 80 mm. Regions were
selected for imaging when tumor parenchyma, stroma, and T cells were simultaneously present in
the same microscopic field. For most of the tumors included in the study, between two and four
microscopic fields were selected for time-lapse experiments.
Dynamic imaging analysis
A 3D image analysis was performed on x, y, and z planes using Imaris 7.4 (Oxford Instruments). First,
superficial planes from the top of the slice to 15 mm in depth were removed to exclude T cells
located near the cut surface. Cellular motility parameters were then calculated. Tracks of >10% of
the total recording time were included in the analysis.
SHG microscopy
The images were obtained using an inverted stand Leica SP5 microscope (Leica Microsystems
GmbH, Wetzlar, Germany) coupled with a femtosecond Ti:sapphire laser (Chameleon, Coherent,
Saclay, France) tuned at a wavelength of 810 or 850 nm for all experiments. The laser beam was cir-
cularly polarized and a Leica Microsystems HCX IRAPO 25/0.95 W objective was used. SHG (colla-
gen structure) signal was detected in epi-collection through a 405/15 nm bandpass filters,
respectively, by NDD PMT detectors (Leica Microsystems) with a constant voltage supply, at con-
stant laser excitation power, allowing direct comparison of SHG intensity values. All images were
then analyzed using CT-FIRE software to obtain the width and the length of the collagen fibers. To
calculate the curvature ratio, line regions were drawn along the length of the fibers (A) and along
the linear distance between the start and the end of the fibers (B), the curvature ratio was calculated
CR = A/B. For each image at least, 15 fibers were analyzed. Fiber alignment was determined using
the directionality plugin in Image J. The fiber alignment was defined by the CV of the angle for all
fibers per image. The smaller the CV is, the more aligned the fibers are.
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Detection of collagen crosslinks using two-photon microscopy
An upright stand Leica SP5 multiphoton microscope (Leica Microsystems) was used to assess PYD
and DPD natural fluorescence within tumor slices of KPC tumors. Samples were illuminated at a
wavelength of 720 nm using a Ti:Sa Chameleon Ultra II (Coherent, Saclay, France) as a laser source.
Fluorescence emissions were measured at a wavelength of 400 ± 25 nm. Mean fluorescent signals
were measured in SHG-positive regions. The background noise of each region was subtracted.
Histology
For most of the tumors, half of the biopsy was fixed overnight at 4˚C in a periodate–lysine–parafor-
maldehyde solution (0.05 M phosphate buffer containing 0.1 M L-lysine [pH 7.4], 2 mg/mL NaIO4,
and 10 mg/mL paraformaldehyde). After fixation, tumors were dehydrated in graded solutions of
ethanol and embedded in paraffin. Five micrometer tissue sections were stained with HES and Sirius
Red. For Sirius Red-stained slices, linear polarized light or bright field microscopy was performed
using full-field microscopy (Statif Axio Observer Z.1, Zeiss) equipped with a linear polarizer and a
20 dry objective (Plan Achromatic [NA = 0.7]). Under polarized light, thin fibers show a greenish-
yellow birefringence, whilst thicker and densely packed fibers give an orange-red birefringence. The
percentage of Sirius Red staining defined the amount of thick and densely packed fibers, to do so
images were split in the RGB channel and the signal in the red channel was quantified.
Atomic force microscopy and shear rheometry
Mechanical measurements of the control and BAPN mice tumors were performed ex vivo at the
nanoscopic and macroscopic scale using AFM and shear rheometer.
AFM experiments were made maximally 3 hr after sample thawing, and tissues were stored and
kept in culture medium during the experiment at room temperature. Millimeter-scale samples of
mice KPC model tumors were measured with a JPK Bruker NanoWizard 4 BioScience atomic force
microscope working in the force spectroscopy mode. Force vs. indentation curves were collected
using a silicon nitride cantilever with a spring constant of 0.6 N=m and a 4.5 mm diameter bead
attached. Each sample was indented in multiple locations to account for possible heterogeneity in
tissue mechanical properties. Briefly, up to nine maps consisting of 64 points corresponding to the
scan area of 10  10 mm (for one map) per sample were made. Final Young’s modulus values were
derived from the Hertz–Sneddon model applied to force vs. indentation curves (Pogoda et al.,
2012), assuming the spherical shape of the probe and Poisson’s ratio equal 0.5. Distributions of
Young’s modulus values for each control and treated sample, as well as the mean values along with
standard deviations, were prepared.
For the macroscopic rheological tests, HAAKE Rheostress 6000 rheometer (Thermo Fisher Scien-
tific), fitted with an 8 mm diameter parallel plate system, was used. Tissues were firstly cut into disk-
shaped samples using an 8 mm punch. To avoid tissue slippage during the tests, samples were
arranged in sand paper glued inside the Petri dishes and fixed to the rheometer bottom plate. Rheo-
logical experiments were made maximally 3 hr after tissue thawing, and all the samples were kept in
humid conditions during the experiment. The rheological evaluation consisted of the oscillating
shear deformation with 2% shear amplitude and frequency of 1 Hz. Final results are presented as the
mean values of storage modulus (G ) of control and treated tumors ± standard deviation (SD) values.
Flow cytometry
Immune cells in tumors were stained as described previously (Peranzoni et al., 2018). In brief,
tumors were mechanically dissociated and digested for 45 min at 37˚C in RPMI 1640 with 37.5 mg/
mL Liberase TM (Roche) and 8,000 U/mL DNase I from bovine pancreas (Merck Millipore). The result-
ing digestion was filtered through a 70 mm cell stainer and centrifuged. Red blood cell lysis with
ACK buffer was performed on the remaining pellet and subsequently filtered on a 40 mm cell
strainer. The cell suspension was then rinsed in PBS and stained in 96-well round-bottom plates with
a LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Invitrogen) for 20 min at 4˚C. Cells were then washed
and stained with Abs against surface proteins at a concentration of 10 mg/mL for 20 min at 4˚C.
The anti-mouse antibodies used were the following:
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Antigen Fluorophore Clone Company
CD11b PE-Cy7 M1/70 Biolegend
CD11b BV421 M1/70 BD Biosystems
CD11c BV605 N418 Biolegend
CD45 AF700 30-F11 Biolegend
Ly-6C APC-Cy7 HK1.4 Biolegend
Ly-6G BV510 1A8 Biolegend
CD4 BV 711 GK1.5 BD Biosciences
CD8a PerCP-e710 53–6.7 eBioscience
TCRb BV605 H57-597 BD Biosciences
Nkp46 eFluor660 29A1.4 eBioscience
PD-1 BV421 29F.1A12 Biolegend
MHC II BV785 M5/114.15.2 Biolegend
CD80 FITC 16-10A1 Biolegend
CD64 PE X54-5/7.1 Biolegend
CD206 BV605 CO68C2 Biolegend
F4/80 StarBright Violet 670 CI:A3-1 BIO-RAD
After surface staining, cells were fixed with BD fixation and permeabilization solution for 20 min
at 4˚C. In the case of intracellular staining, cells were incubated overnight with the following anti-
mouse antibodies. All antibodies were used at a concentration of 10 mg/mL:
Antigen Fluorophore Clone Company
FoxP3 AF488 MF-14 Biolegend
GrzmB PE QA16A02 Biolegend
After washing in PBS, cells were resuspended in PBS 2% FBS and analyzed with a BDFortessa
flow cytometer (BD Bioscience). Data were analyzed by FlowJo software.
Cytokine detection in tumor slice supernatants
Fresh KPC tumor slices were prepared as previously described and kept at 37˚C in 24-well plates
with 0.5 mL RPMI per well. Four to five slices were put in culture for each mouse. Eighteen hours
later supernatants were collected and centrifuged at 300  g to eliminate suspension cells. Cell-free
supernatants were frozen and stored at 80˚C. Granzyme B, TNFa, and RANTES (CCL5) release was
assayed by Luminex technology (Bio-Plex 200 from Bio-Rad) with a customized Milliplex kit (Merck
Millipore).
Statistical analysis
Results were analyzed using the GraphPad Prism 5.0 statistical software. Data are shown as
means ± standard error of the mean (SEM). For comparisons between two groups, parametric Stu-
dent’s t-test or non-parametric Mann–Whitney test were used. For comparisons between more than
two groups, a parametric one-way analysis of variance (ANOVA) test was followed by a posteriori
Kruskal–Walis test.
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. Supplementary file 1. Summary of relevant preclinical models for solid tumors used in this study.
. Supplementary file 2. Tumor stiffness and tumor architecture parameters for EGI-1, KPC, MMTV-
PyMT, mPDAC and MET-1 models. Mean stiffness of tumors with volume > 600 mm3 measured with
SWE. Percentage of stiff regions of tumors with volume > 600 mm3. Tumor architecture was charac-
terized by the percentage of the tumor covered by the stromal compartment, estimated from HES
images; collagen fiber width and length, calculated from SHG images; percentage of red-orange
birefringent fibers combining Red Sirius staining and polarized microscopy, orange-red fibers corre-
spond to thick and packed regions. EGI-1 (n = 30 mice/group from three independent experiments);
KPC (n = 34 mice/group from three independent experiments); MMTV-PyMT (n = 5 mice/group, 10
tumors per mouse from two independent experiments); mPDAC (n = 7 mice/group from two inde-
pendent experiments); and MET-1 (n = 12 mice/group from two independent experiments).
. Supplementary file 3. Collagen fiber width and length in EGI-1, MMTV-PyMT, mPDAC and KPC
tumor models in control and BAPN-treated conditions. Results are shown as mean ± SD.
. Supplementary file 4. T cell migration in the different tumor models and effect of LOX inhibition.
Migration of activated PBT overlaid onto fresh tumor slices was analyzed in EGI-1 and MMTV-PyMT
model, whilst resident tumor infiltrated T lymphocyte migration was analyzed in mPDAC and KPC
models (* p-value<0.05, ***p-value<0.001, Students’ t-test, n = 3–12 mice/group from three experi-
ments, 70–250 T cells per slice analyzed). T cell migration was analyzed at the endpoint of the exper-
iment: day 30 for EGI-1, day 40 for KPC, day 55 for MMTV-PyMT and day 21 for mPDAC. T cell
infiltration (CD8/mm2) calculated from immunofluorescence images. Results are shown as
mean ± SD. Illustrative images of T cell migration tracks in EGI-1 tumor model. Tumor stroma (fibro-
nectin) in red, tumor cells (EpCAM) in blue and T cells (Calcein) in green. Tracks are color-coded to
illustrate track displacement. Scale bar = 100 mm. See also Videos 1 and 2. TILs: tumor-infiltrating T
lymphocytes.
. Transparent reporting form
Data availability
Relevant source data for all figures and supplement figures have been uploaded as Excel files.
References
Anderson KG, Stromnes IM, Greenberg PD. 2017. Obstacles posed by the tumor microenvironment to T cell
Activity: A Case for Synergistic Therapies. Cancer Cell 31:311–325. DOI: https://doi.org/10.1016/j.ccell.2017.
02.008, PMID: 28292435
Baker AM, Bird D, Welti JC, Gourlaouen M, Lang G, Murray GI, Reynolds AR, Cox TR, Erler JT. 2013. Lysyl
oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Research 73:
583–594. DOI: https://doi.org/10.1158/0008-5472.CAN-12-2447, PMID: 23188504
Bordeleau F, Mason BN, Lollis EM, Mazzola M, Zanotelli MR, Somasegar S, Califano JP, Montague C, LaValley
DJ, Huynh J, Mencia-Trinchant N, Negrón Abril YL, Hassane DC, Bonassar LJ, Butcher JT, Weiss RS, Reinhart-
King CA. 2017. Matrix stiffening promotes a tumor vasculature phenotype. PNAS 114:492–497. DOI: https://
doi.org/10.1073/pnas.1613855114, PMID: 28034921
Nicolas-Boluda et al. eLife 2021;10:e58688. DOI: https://doi.org/10.7554/eLife.58688 25 of 29
Research article Cancer Biology
Borowsky AD, Namba R, Young LJ, Hunter KW, Hodgson JG, Tepper CG, McGoldrick ET, Muller WJ, Cardiff
RD, Gregg JP. 2005. Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with
divergent metastatic behavior. Clinical & Experimental Metastasis 22:47–59. DOI: https://doi.org/10.1007/
s10585-005-2908-5, PMID: 16132578
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